{"id":25909,"date":"2025-02-08T15:55:00","date_gmt":"2025-02-08T07:55:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25909"},"modified":"2025-02-08T15:55:02","modified_gmt":"2025-02-08T07:55:02","slug":"sichuan-kelun-biotechs-datailai-gains-nmpa-approval-for-colorectal-cancer-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25909","title":{"rendered":"Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment"},"content":{"rendered":"\n

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990<\/a>) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its pipeline candidate A140, a biosimilar version of Merck KGaA\/Bristol-Myers Squibb\u2019s (BMS) cetuximab (trade name: Erbitux). The drug, to be traded under the name Datailai, is approved for use in combination with FOLFOX or FOLFIRI regimen for the first-line treatment of RAS gene wild-type metastatic colorectal cancer.<\/p>\n\n\n\n

First Biosimilar of Erbitux in China<\/strong>
Erbitux was approved for marketing in the United States in 2004 and gained approval in China the following year. Datailai is the first biosimilar version of Erbitux to be approved in China. The NMPA\u2019s approval is based on results from a randomized, double-blind, controlled, multi-center Phase III study. The study compared Datailai in combination with chemotherapy head-to-head against Erbitux combined with chemotherapy in first-line RAS wild-type metastctal colorectal cancer.<\/p>\n\n\n\n

Clinical Equivalence Demonstrated<\/strong>
Clinical data showed that the Datailai combination had clinical equivalence in objective response rate (ORR) compared to the Erbitux\/chemotherapy combination (71.0% vs 77.5%), with no clinically or statistically significant difference in response duration (mDoR: 10.2 months vs 9.5 months) and progression-free survival (mPFS: 10.9 months vs 10.8 months). Additionally, Datailai was found to be on par with Erbitux in terms of safety, tolerability, and immunogenicity.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval…<\/p>\n","protected":false},"author":1,"featured_media":25911,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,429,428,971,120,15],"class_list":["post-25909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biosimilars","tag-bms","tag-bristol-myers-squibb","tag-hkg-6990","tag-merck","tag-product-approvals"],"yoast_head":"\nSichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its pipeline candidate A140, a biosimilar version of Merck KGaA\/Bristol-Myers Squibb\u2019s (BMS) cetuximab (trade name: Erbitux). The drug, to be traded under the name Datailai, is approved for use in combination with FOLFOX or FOLFIRI regimen for the first-line treatment of RAS gene wild-type metastatic colorectal cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25909\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its pipeline candidate A140, a biosimilar version of Merck KGaA\/Bristol-Myers Squibb\u2019s (BMS) cetuximab (trade name: Erbitux). The drug, to be traded under the name Datailai, is approved for use in combination with FOLFOX or FOLFIRI regimen for the first-line treatment of RAS gene wild-type metastatic colorectal cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25909\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-08T07:55:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-08T07:55:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0811-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"671\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment\",\"datePublished\":\"2025-02-08T07:55:00+00:00\",\"dateModified\":\"2025-02-08T07:55:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909\"},\"wordCount\":224,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0811-png.avif\",\"keywords\":[\"Biosimilars\",\"BMS\",\"Bristol-Myers Squibb\",\"HKG: 6990\",\"Merck\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25909#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25909\",\"name\":\"Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0811-png.avif\",\"datePublished\":\"2025-02-08T07:55:00+00:00\",\"dateModified\":\"2025-02-08T07:55:02+00:00\",\"description\":\"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its pipeline candidate A140, a biosimilar version of Merck KGaA\\\/Bristol-Myers Squibb\u2019s (BMS) cetuximab (trade name: Erbitux). The drug, to be traded under the name Datailai, is approved for use in combination with FOLFOX or FOLFIRI regimen for the first-line treatment of RAS gene wild-type metastatic colorectal cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25909\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0811-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0811-png.avif\",\"width\":1080,\"height\":671,\"caption\":\"Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25909#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment - Insight, China's Pharmaceutical Industry","description":"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its pipeline candidate A140, a biosimilar version of Merck KGaA\/Bristol-Myers Squibb\u2019s (BMS) cetuximab (trade name: Erbitux). The drug, to be traded under the name Datailai, is approved for use in combination with FOLFOX or FOLFIRI regimen for the first-line treatment of RAS gene wild-type metastatic colorectal cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25909","og_locale":"en_US","og_type":"article","og_title":"Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment","og_description":"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its pipeline candidate A140, a biosimilar version of Merck KGaA\/Bristol-Myers Squibb\u2019s (BMS) cetuximab (trade name: Erbitux). The drug, to be traded under the name Datailai, is approved for use in combination with FOLFOX or FOLFIRI regimen for the first-line treatment of RAS gene wild-type metastatic colorectal cancer.","og_url":"https:\/\/flcube.com\/?p=25909","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-02-08T07:55:00+00:00","article_modified_time":"2025-02-08T07:55:02+00:00","og_image":[{"width":1080,"height":671,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0811-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25909#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25909"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment","datePublished":"2025-02-08T07:55:00+00:00","dateModified":"2025-02-08T07:55:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25909"},"wordCount":224,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=25909#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0811-png.avif","keywords":["Biosimilars","BMS","Bristol-Myers Squibb","HKG: 6990","Merck","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25909#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25909","url":"https:\/\/flcube.com\/?p=25909","name":"Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=25909#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=25909#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0811-png.avif","datePublished":"2025-02-08T07:55:00+00:00","dateModified":"2025-02-08T07:55:02+00:00","description":"China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its pipeline candidate A140, a biosimilar version of Merck KGaA\/Bristol-Myers Squibb\u2019s (BMS) cetuximab (trade name: Erbitux). The drug, to be traded under the name Datailai, is approved for use in combination with FOLFOX or FOLFIRI regimen for the first-line treatment of RAS gene wild-type metastatic colorectal cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25909#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25909"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=25909#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0811-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0811-png.avif","width":1080,"height":671,"caption":"Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25909#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0811-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25909"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25909\/revisions"}],"predecessor-version":[{"id":25912,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25909\/revisions\/25912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/25911"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}